News
Revvity Signals Software Unveils Signals Clinical Solution To Accelerate Critical Clinical Trial Insights And Data-Driven Decisions
12 Feb 24
Biotech, News, General
Stifel Maintains Hold on Revvity, Raises Price Target to $110
2 Feb 24
News, Price Target, Analyst Ratings
Keybanc Maintains Overweight on Revvity, Raises Price Target to $126
2 Feb 24
News, Price Target, Analyst Ratings
Raymond James Maintains Outperform on Revvity, Raises Price Target to $127
2 Feb 24
News, Price Target, Analyst Ratings
Revvity Q4 Adjusted EPS $1.25 Beats $1.16 Estimate, Sales $695.90M Beat $677.94M Estimate
1 Feb 24
Earnings, News
Earnings Scheduled For February 1, 2024
1 Feb 24
Earnings
Earnings Preview For Revvity
31 Jan 24
Earnings
The Latest Analyst Ratings For Revvity
25 Jan 24
Analyst Ratings
Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $105
25 Jan 24
News, Price Target, Analyst Ratings
UBS Downgrades Revvity to Neutral, Raises Price Target to $125
16 Jan 24
News, Downgrades, Price Target, Analyst Ratings
Peeling Back The Layers: Exploring Revvity Through Analyst Insights
4 Jan 24
Analyst Ratings
Evercore ISI Group Upgrades Revvity to Outperform, Raises Price Target to $125
4 Jan 24
News, Upgrades, Price Target, Analyst Ratings
Press releases
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group
20 Mar 24
Press Releases
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication
18 Mar 24
Press Releases
Revvity to Present at Upcoming Investor Conferences
21 Feb 24
Press Releases
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023
1 Feb 24
Press Releases
Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors
25 Jan 24
Press Releases
Revvity Board Declares Quarterly Dividend
25 Jan 24
Press Releases